← All indications
Anemia, Hemolytic, Autoimmune
Acquired hemolytic anemia due to the presence of AUTOANTIBODIES which agglutinate or lyse the patient's own RED BLOOD CELLS.
Drugs by status
Approved for this indication (1)
Phase 4 trials (4)
Phase 3 trials (13)
Phase 2 trials (22)
Phase 1 trials (10)
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (7)
Organization Involved with Phase 2 Indications (28)
- Incyte
- Takeda
- Sanofi
- Alexion
- Apellis Pharmaceuticals, Inc.
- National Cancer Institute (NCI)
- Helse Fonna
- University of Pennsylvania
- German CLL Study Group
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Johns Hopkins University
- University of Milan
- University of Oslo
- University of Bergen
- University of Bordeaux
- Mayo Clinic
- University of Cologne
- University of Turku
- University of Udine
- Annexon
- City of Hope National Medical Center
- University of Duisburg-Essen
- Bankura Sammilani Medical College
- Haugesund Hospital
- Assistance Publique - Hôpitaux de Paris
- Kezar Life Sciences, Inc.
- Immunovant Sciences GmbH
- Association of Oncological Hematologists
Organization Involved with Phase 1 Indications (7)
Organization Involved with Other Experimental Indications (1)